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Post-mortem brain investigations of schizophrenia have generated swathes of data in the
last few decades implicating candidate genes and protein. However, the relation of these
findings to peripheral biomarker indicators and symptomatology remain to be elucidated.
While biomarkers for disease do not have to be involved with underlying pathophysiology
and may be largely indicative of diagnosis or prognosis, the ideal may be a biomarker
that is involved in underlying disease processes and which is therefore more likely to
change with progression of the illness as well as potentially being more responsive
to treatment. One of the main difficulties in conducting biomarker investigations for
major psychiatric disorders is the relative inconsistency in clinical diagnoses between
disorders such as bipolar and schizophrenia. This has led some researchers to investigate
biomarkers associated with core symptoms of these disorders, such as psychosis. The
aim of this review is to evaluate the contribution of post-mortem brain investigations to
elucidating the pathophysiology pathways involved in schizophrenia and psychosis, with
an emphasis on major neurotransmitter systems that have been implicated. This data
will then be compared to functional neuroimaging findings as well as findings from blood
based gene expression investigations in schizophrenia in order to highlight the relative
overlap in pathological processes between these different modalities used to elucidate
pathogenesis of schizophrenia. In addition we will cover some recent and exciting findings
demonstrating microRNA (miRNA) dysregulation in both the blood and the brain in patients
with schizophrenia. These changes are pertinent to the topic due to their known role in
post-transcriptional modification of gene expression with the potential to contribute or
underlie gene expression changes observed in schizophrenia. Finally, we will discuss how
post-mortem studies may aid future biomarker investigations.
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INTRODUCTION
The official national institute of health (NIH) definition of a
biomarker is, “a characteristic that is objectively measured and
evaluated as an indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic interven-
tion” (Nih, 2001). Investigations of blood-based biomarkers for
schizophrenia have great potential in discovering diagnostic or
prognostic indicators of clinical utility and may provide clues
to the underlying pathophysiology as the blood is a dynamic,
sentinel tissue that is known to reflect immune and patholog-
ical status (Gladkevich et al., 2004). Data from post-mortem
investigations of gene and protein expression in schizophrenia
can act two-fold in order to aid blood-based biomarker discov-
ery. They may act to drive blood-based biomarker investigations
by the genes, proteins, or structures that have been previously
implicated, or conversely, as a means of extending findings seen
in blood-based biomarker investigations. While biomarkers for
disease do not need to have pathophysiological roles and can be
utilized to detect presence or absence of disease, the ideal sce-
nario maybe the identification of biomarkers that are involved
in etiological pathways and are therefore likely to change accord-
ing to disease status as well as potentially being responsive to
treatments. Over the last two decades numerous post-mortem
neuropathological investigations have implicated a number of dif-
ferent proteins in the pathogenesis of major psychiatric disorders,
including schizophrenia, bipolar disorder, and major depressive
disorder. Although some of these findings have been corroborated
independently, many of them remain controversial and conflict
with follow-up investigations. Similarly, gene association stud-
ies have been plagued with inconsistencies, with regards to genes
implicated in individual populations falling out in meta-analyses
or large independent replication efforts failing to validate ini-
tial findings. The advent of microarray technology, coupled with
the mapping of the human genome, has greatly aided the ability
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to investigate larger numbers of genes simultaneously. While a
number of these investigations have led to the generation of
false-positive and -negative findings in terms of disease related
gene expression changes some consistent trends are beginning to
emerge.
In post-mortem gene expression investigations, alterations
in the expression of transcripts encoding for oligodendrocyte
functioning and myelination have been observed in the PFC in
schizophrenia (Hakak et al., 2001; Tkachev et al., 2003, 2007;
Aston et al., 2004, 2005; Kerns et al., 2010) and also in bipo-
lar and major depressive disorder (Tkachev et al., 2003; Aston
et al., 2005; Sun et al., 2006; Kim and Webster, 2011). These
include genes encoding for major myelin components such as
myelin basic protein (MBP) as well as myelin oligodendrocyte
basic protein (MOBP). Such genes have been postulated to be
involved in higher cognitive functions (Nave, 2010), functions
which are compromised in patients with schizophrenia. While the
functions of genes such as MOBP are not fully understood they
are likely to have a significant role in the compaction of myelin
sheaths, thereby aiding brain connectivity and signaling. Post-
mortem schizophrenia investigations have also revealed decreased
myelin thickness (Flynn et al., 2003) and damaged myelin sheaths
(Uranova et al., 2011). In addition, recent diffusor tensor imag-
ing (DTI) studies have demonstrated improvement in myelin
integrity upon exposure to anti-psychotics in treatment respon-
sive patients (Garver et al., 2008; Bartzokis et al., 2012), suggesting
an alternative mechanism of action that may provide new targets
for future development (Walterfang et al., 2011; Ren et al., 2013).
Genes related to metabolism and mitochondrial pathways are
another ontological group that have been found by a number of
studies to be reduced in expression in the PFC in schizophre-
nia (Pongrac et al., 2002; Tkachev et al., 2003; Prabakaran et al.,
2004; Iwamoto et al., 2005; Konradi, 2005) and by some in bipo-
lar disorder (Iwamoto et al., 2005). While the association of
these genes with the disorders themselves may be evidenced, their
mechanism of action in causing symptoms associated with the
disorders remains to be elucidated. However, some studies have
demonstrated that changes in gene expression are also a func-
tion of duration of illness which could be related to changing
symptom profile that occurs with progression of illness (Narayan
et al., 2008; Tang et al., 2009, 2012). Teasing out this etiological
component is confounded by major psychiatric disorders having
overlapping symptomatology, and in the case of schizophrenia
and bipolar disorder sometimes leading to differential diagno-
sis. This problem, has prompted some researchers to look at
key characteristic such as psychosis that provide a more tangi-
ble target to assess similarities and differences in etiology between
disorders. This review will begin with an overview of the main
post-mortem findings contributing to our understanding of the
etiology and pathophysiology of schizophrenia and psychosis.
Following this, current literature relating to blood-based gene
expression studies in patients with schizophrenia and how they
relate to post-mortem data will be discussed as well as the future
direction of post-mortem investigations to validate blood-based
biomarker findings. In relation to regulation of gene expres-
sion we will also discuss recent interesting findings of microRNA
(miRNA) dysregulation in schizophrenia.
POST-MORTEM DATA ELUCIDATING PATHOPHYSIOLOGY
PATHWAYS IN SCHIZOPHRENIA
DOPAMINERGIC SYSTEM
Numerous post-mortem investigations in schizophrenia have
implicated several neurotransmitter systems in having a patho-
physiological role. The first of these centered on the dopaminergic
system, primarily driven by the fact that neuroleptic medications
had a high affinity for D2 receptors which correlated with their
therapeutic effect at alleviating positive symptoms (Meltzer and
Stahl, 1976).While this is supported by the observation that drugs
such as amphetamine, cocaine and methamphetamine (METH)
all increase dopaminergic transmission and are capable of induc-
ing psychosis (Janowsky and Risch, 1979; Chen et al., 2003), other
drugs such lysergic acid diethylamide (LSD), ketamine and phen-
cyclidine (PCP) that also have the ability to produce psychosis
do so without pronounced effects on the dopaminergic system.
While early studies reported increased D2 receptor density in
patients with schizophrenia vs. controls, these investigations did
not control for the patients receiving neuroleptic medication and
subsequent studies controlling for this confound (Reynolds et al.,
1981; MacKay et al., 1982; Kornhuber et al., 1989) or having
appropriately designed methodology (Dean et al., 1997) failed
to detect differences. Post-mortem investigations have also found
evidence for dysregulation in the gene for catechol-o-methyl
transferase (COMT), encoding for the enzyme that degrades
dopamine. These investigations have found that COMT gene
expression is inversely correlated with gene expression of regu-
lator of g-protein signalling-4 (RGS4) (Lipska et al., 2006), with
substitutions at Val158Met in COMT significantly reducing the
activity of COMT (Chen et al., 2004). These investigations are
in keeping with a substantial gene association literature impli-
cating polymorphism in COMT to schizophrenia susceptibility
(Shifman et al., 2002; Tunbridge et al., 2006). However, as for
many genes in the schizophrenia literature meta-analytic review
of gene association investigations implicating COMT have shown
that the findings of association do not hold up when comparing
across studies (Glatt et al., 2003).
CHOLINERGIC SYSTEM
The cholinergic muscarinic receptors (CHRM) have been impli-
cated in the pathophysiology of schizophrenia as well as mood
disorders, where psychosis can present as part of the symptoma-
tology (Crook et al., 2000; Gibbons et al., 2009). In schizophrenia,
post-mortem studies of the cortex point to the involvement
of CHRM1, with the recent identification of a sub-type of
schizophrenia with widespread loss of cortical and sub-cortical
CHRM1 protein expression (Scarr et al., 2009; Gibbons et al.,
2013). These post-mortem studies have been supported by a
neuroimaging study demonstrating a reduction in muscarinic
receptor availability in unmedicated patients with schizophrenia
(Raedler et al., 2003) Whereas, post-mortem, neuroimaging, and
genetic association studies implicate CHRM2 in the pathophysi-
ology of mood disorders (Wang et al., 2004; Gibbons et al., 2009).
Interestingly, elucidating the role of the cholinergic system in the
etiology of psychosis has been aided by studies into Alzheimer’s
disease where the CHRM1/CHRM4 partial agonist Xanomeline
can reduce psychotic symptoms (Bymaster et al., 1997; Shekhar
Frontiers in Cellular Neuroscience www.frontiersin.org June 2013 | Volume 7 | Article 95 | 2
Chana et al. Pathophysiological pathways in schizophrenia
et al., 2008). The cholinergic system has also been implicated
in acute stress with inhibitors of the acetylcholine-hydrolyzing
enzyme acetylcholinesterase (AChE) producing symptoms of
depression and cognitive decline in mice via potentiation of
acetylcholine signaling (Kaufer et al., 1998). In addition, a recent
study inmice found that anxiety and depression behaviors elicited
through administration of physostigmine, an inhibitor of AChE
could be reversed with administration of nicotinic and mus-
carinic receptor antagonists (Mineur et al., 2013). These studies
point to the potential of drugs that target the cholinergic sys-
tem in alleviating some of the negative symptoms associated with
schizophrenia, something that is poorly addressed by current
antipsychotic medications.
Murine knockout models have shown that the antipsy-
chotic effects of Xanomeline are predominantly mediated
via CHRM4, which in turn modulates dopaminergic activ-
ity (Woolley et al., 2009). Post-mortem studies have also
reported reduced binding of the radioligand [3H]4-DAMP, under
CHRM1/CHRM3/CHRM4/CHRM5 selective assay conditions,
in the orbitofrontal cortex from subjects with Alzheimer’s dis-
ease who had significant psychotic symptoms (Tsang et al., 2008).
Conversely, elevated levels of the cortical autoreceptor CHRM2
(Zhang et al., 2002) are associated with behavioral disturbances
in both Alzheimer’s disease and Lewy body dementia (Lai et al.,
2001; Teaktong et al., 2005) pointing to a hypocholinergic state
associated with psychosis. In schizophrenia, subjects with deficits
in CHRM1 protein expression also show a reduction in cortical
and subcortical binding of [3H]AF-DX 384, a CHRM2/CHRM4
selective radioligand (Gibbons et al., 2013). The reduction in
hippocampal CHRM4 mRNA levels in schizophrenia suggests
this loss of binding reflects a loss of CHRM4 protein expres-
sion (Scarr et al., 2007). Within the cortex, [3H]AF-DX 384
binding is reported to be unchanged in the ACC in schizophre-
nia. However, there is contrasting data relating to the role of
CHRM4 in schizophrenia (Crook et al., 1999; Zavitsanou et al.,
2005; Gibbons et al., 2013). Thus, cholinergic involvement in
psychosis may be specific to a sub-type within schizophrenia.
Importantly, a SPECT study has reported reduced binding den-
sities of the broadly selective CHRM radioligand [123I]IQNB in
patients with schizophrenia (Raedler et al., 2003) raising the pos-
sibility of clinical identification of individuals within this subtype
using neuroimaging.
GLUTAMATERGIC SYSTEM
A role for glutamate, the primary excitatory neurotransmit-
ter in the brain, has long been evidenced from observa-
tions that drugs such as ketamine and phencyclidine (PCP)
that primarily block iontropic n-methyl-d-aspartate receptors
(NMDARs) and are capable of causing negative and positive
symptoms that resemble those seen in psychotic disorders such
as schizophrenia (Luby et al., 1962; Vollenweider and Geyer,
2001; Pomarol-Clotet et al., 2006). This observation led to the
NMDA hypofunction hypothesis of schizophrenia (Olney and
Farber, 1995) with the involvement of the glutamatergic system
in psychosis stemming from neuroimaging, genetic, and post-
mortem investigations. In support of a glutamatergic dysfunc-
tion in schizophrenia, kainate receptor expression is decreased
in the dlPFC in schizophrenia (Scarr et al., 2005), while hip-
pocampal expression of the NR1 and NR2B subunits of the
NMDA receptor are increased and decreased, respectively (Gao
et al., 2000). Other studies have shown that NMDARs are likely
involved with schizophrenia including early studies demonstrat-
ing that glutamate carboxypeptidase II (GCPII) that catabolizes
N-Acetylaspartylglutamic acid (NAAG) to NAA and glutamate
was reduced in the frontal cortex, hippocampus and tempo-
ral lobe in patients with schizophrenia vs. controls (Tsai et al.,
1995) as well as more recent evidence demonstrating that GAD67
neurons co-expressing NR2A are reduced in the prefrontal cor-
tex in patients with schizophrenia (Woo et al., 2004, 2008).
Increased mRNA and protein levels of the glutamate trans-
porters EAAT1, EAAT3, and EAAT4 have also been reported in
schizophrenia (Rao et al., 2012). Furthermore, many of the genes
that have consistently been associated with schizophrenia, such
as NRG1, RGS4, DTNBP1, and DAAO are involved in regula-
tion of glutamatergic neurotransmission, with the antipsychotic
clozapine being shown to increase levels of NRG1 as well as
vesicle-associated membrane protein-1 (VAMP1) in human pri-
mary cultures exposed at steady state plasma levels (Chana et al.,
2009), indicating that NRG1 may be a possible therapeutic target.
Indeed NRG1 signaling through ErbB4 receptors have the capac-
ity to determine NMDA efficacy, with NMDA receptor activity
playing a key role in the development and stability of synaptic
spines (Bennett, 2009), with stress responses and activation of the
glucocorticoid receptor system also causing synaptic regression
(Bennett, 2008).
With regards to modulation of NMDA receptors and the
NMDA hypofunctioning hypothesis of schizophrenia, DAAO is
of particular interest due to its metabolism of d-serine, a known
allosteric modulator and necessary co-agonist for NMDA recep-
tors (Oliet and Mothet, 2009). DAAO levels have been found to
be elevated in both the brain and cerebrospinal fluid (CSF) of
patients with schizophrenia (Bendikov et al., 2007; Madeira et al.,
2008; Habl et al., 2009). This in turn results in a reduction in the
breakdown of d-serine and could facilitate NMDA hypofunction-
ing. In relation to psychosis, DAOA has recently been linked to
progression to a first episode of psychosis in prodromal subjects
(Mossner et al., 2010). Another two important proteins that sup-
port such a hypothesis are d-serine racemase, a predominantly
astrocytic enzyme that converts l-serine to d-, and d-amino-acid
oxidase activator (DAOA) that as it name suggests may be respon-
sible for the activation of DAAO and hence subsequent break-
down of d-serine. However, while one would expect that serine
racemase would be reduced in a scenario of NMDA hypofunc-
tioning i.e., reduced d-serine production and therefore reduced
NMDA activation, increased serine racemase has been reported
within the frontal cortex in a post-mortem study of schizophrenic
subjects (Verrall et al., 2007) as well as decreased (Bendikov et al.,
2007). In addition, an earlier study reported no change in the cor-
tex but an increase in expression within the hippocampus (Steffek
et al., 2006). Therefore, as a correlate for NMDAhypofunctioning
further characterization is required in independent brain cohorts
before a firm conclusion can be reached. The evidence for DAOAs
involvement in psychosis has been growing with several genetic
studies finding an association between polymorphisms in the
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G72 gene which encodes DAOA, and the development of psy-
chosis (Addington et al., 2004; Craddock et al., 2005; Mossner
et al., 2010) as well as severity of positive symptoms (Chiesa
et al., 2011). In addition, a recent investigation demonstrated that
polymorphisms within the G72 gene were associated with a vul-
nerability to methamphetamine psychosis (Kotaka et al., 2009).
While the data from the study may seem damning to aspirations
of DAOA as a susceptibility gene for psychosis, the authors for
this study did not differentiate between brain regions other than
the amygdala and the caudate nucleus. Therefore, it was unclear
whether key brain regions such as the PFC were included and in
what proportions. Furthermore, there is also a need for separation
of cortical and subcortical matter due to potential differences in
expression that may exist between them.
GABAergic SYSTEM
Gamma-amino-butyric-acid (GABA) has been implicated for a
number of years in schizophrenia following a number of post-
mortem investigations demonstrating its dysregulation within
the brain. The most consistent of these changes and indeed one
of the most consistent post-mortem neuropathological changes
observed for schizophrenia were reductions in GABAergic mark-
ers such as glutamic acid decarboxylase-67 (GAD-67), the syn-
thesizing enzyme for GABA, within the PFC (Akbarian et al.,
1995; Guidotti et al., 2000; Volk et al., 2000; Veldic et al.,
2005; Akbarian and Huang, 2006) as well as the temporal cor-
tex (Impagnatiello et al., 1998; Heckers et al., 2002; Akbarian
and Huang, 2006) and hippocampus (Thompson et al., 2011).
In relation to these studies, and as a potential link for GABA’s
involvement in psychosis, Veldic et al. (2005) demonstrated a
decreased number of neurons expressing mRNA for GAD-67
within the PFC of brains from schizophrenia and bipolar subjects
with a history of psychosis with a concomitant increase in corti-
cal DNA-methyltransferase I (DNMT1), an enzyme preferentially
expressed by interneurons, causing a possible down-regulation
of promoter functioning within these cells (Veldic et al., 2005).
Reductions in GABAergic functioning have also been evidenced
by reduced expression of a number of the subunits making up
the GABAA receptor by (Charych et al., 2009). Furthermore,
while GAD-65 and GAD-67 mRNA expression has been shown
to be either reduced or unchanged within the layers of the hip-
pocampus in subjects with schizophrenia (Benes et al., 2007),
increases in GAD-65/67 immunoreactive neuronal density has
been reported in the subiculum and parahippocampal gyrus
from chronically medicated cases (Schreiber et al., 2011); sug-
gesting that increasing GABA synthesis may be a function of
antipsychotics.
SEROTONINERGIC SYSTEM
While blockade of D2 receptors would seem to be a requirement
for both typical and atypical antipsychotic medications in alle-
viating positive symptoms, atypicals such as clozapine are also
known to have a high affinity for serotonergic receptors, in par-
ticular 5HT2A receptors (2ARs) (Meltzer, 1992). This observation
has led some researchers to elucidate a possible role for serotonin
in both the positive and negative aspects of schizophrenia. While
many post-mortem studies have demonstrated decreases in 2ARs
(Burnet et al., 1996; Dean et al., 1996; Kouzmenko et al., 1997)
a recent study by Gonzalez-Maeso et al. (2008) demonstrated an
upregulation of 2ARs, and a concomitant decrease in mGLUR2
within the PFC of untreated patients who had schizophrenia.
(Gonzalez-Maeso et al., 2008). One important aspect of this study
that distinguishes it from previous post-mortem investigations of
2AR was that the brains of their subjects who had schizophre-
nia were anti-psychotic naïve and therefore changes in expression
could not be explained medication effects. Indeed in order to bet-
ter understand the discrepancy between their findings and others
the authors investigated 2AR expression changes associated with
treating mice with the atypical antipsychotic clozapine and typical
antipsychotic haloperidol. They found that clozapine downreg-
ulated 2AR expression in the somatosensory cortex while this
effect was not seen for haloperidol. While the potential cross-
talk between mGLUR2 and 2AR may have been demonstrated
within this investigation and is of interest, a major oversight by
the authors was in not commenting on the impact of a high num-
ber of suicide victims in their schizophrenia cohort, with 87.5% of
all cases dying by this mode, compared to a rate of 4.9% estimated
in a recent re-examination of rates within the schizophrenia pop-
ulation (Palmer et al., 2005). This is of importance given that
2ARs have been demonstrated to be elevated within the frontal
cortex of victims of suicide (Stanley and Mann, 1983; Arranz
et al., 1994; Turecki et al., 1999), which in turn could potentially
explain the elevated 2ARs seen in their study. However, the pro-
posed role for 2AR in psychotic illness is concordant with findings
in Parkinson’s disease where binding the 2AR radioligand [3H]
ketanseron is increased in cases with a history of visual halluci-
nations (Huot et al., 2010). While evidence has been mounting
for the independent contributions of each of the aforementioned
neurotransmitter systems to the development of psychosis the co-
ordination or dysregulation between neurotransmitters is a more
logical likely causation of psychosis. This interactive approach
when viewing neurochemical abnormalities in schizophrenia and
psychosis has come about in part due to our understanding of
individual neurotransmitter systems and how they intermingle
to regulate the action of one another. It has also come about
following a realization that psychosis-related disorders are too
complex for their pathophysiology to be underpinned by a single
neurotransmitter.
FUNCTIONAL NEURO-IMAGING DATA ELUCIDATING
PATHOPHYSIOLOGY PATHWAYS IN SCHIZOPHRENIA
Over the last decade the power of functional neuroimaging stud-
ies to characterize pathophysiological pathways in schizophrenia
has greatly increased, especially in the advancement of studies
using positron emission tomography (PET) and single-photon
emission computed tomography (SPECT) that are techniques
allowing the visualization in real-time of changes in recep-
tor densities related to neurotransmitter and signaling systems.
Importantly,thishasallowedthevalidationofpost-mortemfindings
as well as expansion of implicated pathways for schizophrenia.
DOPAMINERGIC SYSTEM
Probably the most well-investigated neurotransmitter system
using these imaging modalities has been the dopaminergic
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system. As a main molecular target for antipsychotic medica-
tions, dopamine, and D2 receptor binding has been studied by a
number of investigations utilizing nuclear magnetic spectroscopy
(NMS) as well as PET and SPECT, with the caudate nucleus
being the brain area most heavily investigated due to it’s high
D2 receptor density. While some investigations utilizing NMS
have reported increased binding in drug naïve and late onset
schizophrenia patients (Tune et al., 1993, 1996; Pearlson et al.,
1995) others have failed to detect such changes (Hietala et al.,
1994; Nordstrom et al., 1995). This lack of congruence amongst
studies may represent differing methodologies and pharmacology
of radioligands used (Dean, 2012), but may also be indicative of
a similar lack of consistency for D2 receptor density and occu-
pancy in post-mortem brain tissue. Potential confounders of
these investigations are age and duration of illness, with post-
mortem studies showing that D2 occupancy decreases with age
(Rinne et al., 1993; Dean et al., 1997) and more recent evidence
demonstrating that gene expression of D2 changes according to
increasing duration of illness (Dean et al., 2007). Similar contro-
versy has surrounded investigations in schizophrenia that assessed
levels of dopamine-D1 like receptors, with decreases reported in
a number of different brain regions (Okubo et al., 1997; Kosaka
et al., 2010) in contrast shown to be increased by others (Abi-
Dargham et al., 2012). In addition, post-mortem studies also
reflect variability in findings related to D1 receptor levels (Seeman
et al., 1987; Knable et al., 1994; Dean, 2012). Amajor confounding
variable of these studies is likely related to the variation in med-
ication histories between individuals. As for dopamine receptors,
PET and SPECT studies assessing levels of dopamine transporter
(DAT) have also produced inconsistency in findings, with some
investigations reporting decreased DAT levels (Laakso et al., 2001;
Mateos et al., 2007) but with themajority of investigations report-
ing no differences (Kuepper et al., 2012). Therefore, the change
in DAT levels, if present in schizophrenia, are likely to be of
a small magnitude. While dopamine receptor and transporter
studies have failed to show consistent changes in patients with
schizophrenia, investigations aimed at assessing dopamine syn-
thesis and release have provided evidence for neurotransmitter
changes in the striatum. Using [18F]flurodopamine a number of
studies have demonstrated increased uptake of this radioligand in
the striatum in patients with schizophrenia (Hietala et al., 1995,
1999; Laruelle et al., 1996). These findings are also consistent
with amphetamine-induced dopamine release being significantly
increased in the striatum of patients with schizophrenia using the
ligand [123]iodobenzamide (Laruelle et al., 1996) and while it
could be argued that these changes may be related to medica-
tion effects, increased dopamine release has also been observed
in drug-naïve and drug free patients (Abi-Dargham et al., 1998,
2009). These findings warrant further investigation in additional
cohorts.
CHOLINERGIC SYSTEM
While post-mortem investigations of the cholinergic system have
revealed evidence for decreases in M1 receptors in schizophrenia
(Scarr et al., 2009; Gibbons et al., 2013), functional neuroimaging
investigations of the cholinergic system have been less numer-
ous. Nevertheless, a study using the ligand [123]iodoquinclidinyl
benzilate ([123I]IQNB) reported widespread reductions in mus-
carinic receptors in the brains of drug free schizophrenia
patients(Raedler et al., 2003). Given that reductions inmuscarinic
receptors have also been observed in bipolar disorder and major
depressive disorder (Gibbons et al., 2009) the investigation of
the muscarinic system as a common system affected in major
psychiatric disorders may be warranted.
GLUTAMATERGIC SYSTEM
With ketamine and PCP capable of causing psychosis through
NMDA receptor blockade the limited number of functional imag-
ing studies for glutamate in schizophrenia have focused on char-
acterizing potential changes in NMDA signaling. These studies
have shown that there is no change in the thalamus and striatum
using the ligand [123] CNS 1261 (Bressan et al., 2003), with the
same group showing that there was a decrease in NMDA recep-
tors in the left hippocampus (Pilowsky et al., 2006). With growing
evidence that the glutamatergic system plays an important role in
the etiology of schizophrenia, including the role of metabotropic
glutamate receptors and their cross-talk with NMDA receptors,
further functional neuroimaging investigations generating lig-
ands for other glutamatergic targets is a likely outcome within the
next decade.
GABAergic SYSTEM
While GABAergic dysfunction in schizophrenia has been elu-
cidated by a number of post-mortem investigations demon-
strating alterations in interneuronal populations in the frontal
and cingulate cortices, imaging studies have been limited with
regards to assessing functional changes in GABA transmission.
Investigations that have looked at GABAA receptors have found
that there are no changes in levels of this receptor in the brain in
patients with schizophrenia (Busatto et al., 1997; Abi-Dargham
et al., 1999; Verhoeff et al., 1999). In addition, a PET investiga-
tion that investigated levels of the central benzodiazepine receptor
(cBZr) located on the GABAA receptor in patients with anxiety
and controls found no differences (Abadie et al., 1999).
SEROTONERGIC SYSTEM
The focus of functional neuroimaging studies in relations to the
serotonergic system has been on the 5HT2AR receptors, due to
clozapine, as the first of the second generation antipsychotic med-
ications demonstrating a high affinity at 2ARs (Meltzer, 1992).
Interestingly, as for the post-mortem studies, decreased 2ARs
have also been observed by PET studies (Ngan et al., 2000;
Rasmussen et al., 2010), with the latter of these studies being
carried out in drug-naïve subjects. Decreased 2AR density has
additionally also been seen in individuals at risk of develop-
ing mental illness (Hurlemann et al., 2008). Contrary to these
investigations, however, a study conducted in first-episode neu-
roleptic naïve subjects found a 40% increase in 2ARs (Erritzoe
et al., 2008). This controversy in functional neuroimaging studies
mirrors that for post-mortem brain tissue and also reflects find-
ings above for other neurotransmitter systems. With an increase
in superior ligands for neurotransmitter receptors in the com-
ing years, a consensus on in vivo receptor changes and how they
relate to post-mortem findings will be important in order for
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us to better understand longitudinal changes in these receptor
populations according to disease.
BLOOD BASED GENE EXPRESSION INVESTIGATIONS IN
SCHIZOPHRENIA
For psychotic and brain disorders the CSF represents the most
obvious choice as a tissue source for detecting biomarkers in
living individuals. However, as obtaining CSF samples is a sub-
stantially more invasive procedure than simply drawing blood,
a rapidly growing number of investigations have focused on the
use of blood to search for biological indicators of psychosis and
schizophrenia. Early blood based biomarker investigations found
evidence for alterations in neurotransmitter expression within
blood platelets from patients with schizophrenia. These stud-
ies included a positive correlation between dopamine uptake
from platelets from patients with schizophrenia and delusional
state (Tateno et al., 2013) as well as increases in platelet 5HT-2
receptors that is increased further following treatment with
fluphenazine and trifluoperazine (Amato et al., 2011). A more
recent study has demonstrated that loxapine treatment downreg-
ulates both D2-like and 5HT-2A in platelets from patients with
schizophrenia (Nord and Farde, 2011), with the latter finding
being contradictory to that by Pandey et al. Further evidence indi-
cating that platelets of patients with schizophrenia may provide
a suitable tissue for a source of biomarker discovery has come
from another recent study demonstrating that platelets derived
from patients with schizophrenia demonstrated hypoglutamater-
gic release of Ca2+ (Miyake et al., 2011). Further characterization
work is needed in order to uncover what other neurotransmitter
receptors these cells express.
A number of recent blood-based expression studies have
utilized lymphoblastoid cells cultured from patients with
schizophrenia and bipolar disorder. The earliest one of these
studies was that by Kakiuchi et al. (2003) in which a reduction
in expression of X-box binding protein 1 (XBP1) in a pair of
twins discordant for bipolar disorder vs. a control twin pair was
reported. XBP1 is a pivotal gene in the endoplasmic reticulum
(ER) stress response and therefore is of interest given elevation
of stress response molecules such as cortisol in patients with
bipolar disorder. In addition, they found that a polymorphism
substitution at position 116 (C—G) in the promoter region of
XBP1 lymphoblasts derived from Japanese patients with bipolar
disorder conferred a reduced ER stress response that was res-
cued by treatment with the mood stabilizer valproate (Kakiuchi
et al., 2003). More recently, they extended their findings by
demonstrating that lithium treatment also was more effective in
patients with the 116C allele as opposed to patients homozy-
gous for 116G (Kakiuchi et al., 2006). While this finding directly
relates the codon substitution to a knownmood-stabilizing agent,
validation of this interesting finding in a separate larger inde-
pendent patient cohort is warranted. In the largest microarray
study of lymphoblastoid cells so far by Vawter et al. (2004) it
was found that the expression of neuropeptide Y (NPY) and the
gene that encodes for Guanine nucleotide-binding protein G(o)
subunit alpha (GNA01) were reduced in schizophrenia and there
was an increase in the mitochondrial-related gene malate dehy-
drogenase 1, NAD (MDH1) (Vawter et al., 2004). Changes in
NPY have been observed by some post-mortem investigations in
schizophrenia and bipolar disorder and are therefore of interest
(Frederiksen et al., 1991; Iritani et al., 2000; Kuromitsu et al.,
2001). It should be noted that even for this study sample num-
bers were relatively small with only 5 patients with schizophrenia
and 9 controls. Moreover, studies that used lymphoblastoid cell
lines utilized Epstein Barr virus (EBV) to transform PBMCs, an
effect which in itself could lead to changes in gene expression.
Peripheral blood microarray findings have implicated sensory
and motor neuron derived factor (SMDF), a splice variant of
NRG1, in patients with schizophrenia (Petryshen et al., 2005).
In addition, decreased gene expression of NRG1 and dystro-
brevin binding protein 1 (DTNBP1) were shown to be lower
in immortalized lymphocytes from patients with schizophre-
nia vs. controls before and after treatment with the antipsy-
chotic olanzapine (Chagnon et al., 2008). However, a follow-up
study failed to report changes in NRG1, DTNBP1, or GNAO1
in patients with schizophrenia vs. controls (Yamamori et al.,
2011). Reduced expression of NRG1 has also been observed
in PBMCs from first-onset schizophrenia patients compared to
controls, which normalized following treatment with antipsy-
chotic medications (Zhang et al., 2008). Interestingly, another
microarray gene expression investigation using whole blood
from patients with schizophrenia and assessing gene expres-
sion changes related to positive symptomatology, found that
NRG1 was increased relative to higher delusional states (Kurian
et al., 2011). This contradictory finding may be a consequence
of a lack of control group for the latter investigation or may
be related to the separation of symptomatology that was car-
ried out. This finding for NRG1 reflects the genetic association
studies that have found a susceptibility for schizophrenia as
well as recent evidence for reduced NRG1 levels in the PFC of
brains of patients with schizophrenia and unipolar depression
(Bertram et al., 2007). While some studies have failed to demon-
strate association of NRG1 to schizophrenia, (Thiselton et al.,
2004; Duan et al., 2005; Rosa et al., 2007) recent meta-analyses
have supported a relationship (Li et al., 2006; Munafo et al.,
2006). ImpairedNRG1migration of B-lymphocytes isolated from
patients with schizophrenia vs. controls has also been demon-
strated that was associated with polymorphisms in NRG1 and
the gene for catechol-o-methyl-transferase [COMT (Sei et al.,
2007)], an enzyme required for degradation of neurotransmit-
ters including dopamine and that has also been heavily implicated
in schizophrenia via association studies (Williams et al., 2007).
However, it is important to mention that findings forCOMT have
been relatively inconsistent and a recent meta-analysis failed to
find an association with COMT and susceptibility to schizophre-
nia (Okochi et al., 2009). Of relation to biomarkers of dopamin-
ergic signaling, another investigation also demonstrated that the
number of leukocytes expressing dopamine and cyclic adeno-
sine 3′′:5′′-monophosphate regulated phosphoprotein of relative
molecular mass 32,000 (DARPP-32) was reduced within PBMC
sub-populations in schizophrenia and bipolar disorder (Williams
et al., 2007; Torres et al., 2009).
In a comparative blood and brain gene expression study
we demonstrated that the gene for selenium binding protein-1
(SELENBP1) was upregulated in both compartments in
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schizophrenia and was validated in the blood using qRT-PCR
and immunohistochemistry (Glatt et al., 2005). In a follow-up
qRT-PCR study looking at a separate brain cohort, our group
also observed increased SELENBP1 expression in the dlPFC of
patients with schizophrenia (Kanazawa et al., 2008). Interestingly,
the expression of SELENBP1 was significantly correlated with
psychosis in a combined sample of schizophrenia and bipolar
disorder patients regardless of their diagnosis. In contrast to
these findings, a study of 30 patients first hospitalized for a
psychotic episode with symptoms consistent with schizophrenia
(n = 15), schizophreniform disorder (n = 13) or schizoaffective
disorder (n = 2) investigated levels of SELENBP1 in PBCs after
commencement of treatment. Using qRT-PCR, SELENBP1
was compared between patients with a psychotic disorder and
controls; there was no significant difference between the groups
(Yao et al., 2008). Nevertheless, a recent study investigated
the expression of SELENBP1 in BA46 from 13 subjects with
major depressive disorder (MDD), 11 subjects with MDD and
psychotic features and 12 controls (Teyssier et al., 2011). There
was no significant difference in the expression of SELENBP1
between subjects with psychotic features and controls, or subjects
with a depressive disorder and controls (Teyssier et al., 2011).
The authors argued that results demonstrate that SELENBP1
expression is not a marker of psychosis; however, the sample
size was small and may not have sufficient power to detect a
difference in the expression of SELENBP1. SELENBP1 is localized
to chromosome 1q21, which has previously been identified
as a susceptibility locus for schizophrenia (Brzustowicz et al.,
2000), which indicates that the upregulation of SELENBP1
in psychotic disorders may be involved in the susceptibility
to psychosis. While increased expression of SELENBP1 in the
dlPFC in schizophrenia may be present, the functional relevance
of this upregulation remains to be elucidated. One potential
mechanism may be related to its potential role as a neurogenic
factor evidenced by two investigations demonstrating its ability
to promote neurite outgrowth; in the rat cerebral cortex (Zhao
et al., 2000) as well as co-localization with actin in growing tips
of human neuroblastoma SH-SY5Y cells (Miyaguchi, 2004).
Given that reductions in synaptic and dendritic arbors have been
observed in the brains of patients with schizophrenia, elevated
SELENBP1 may play a compensatory role in restoring neuronal
connectivity and functioning. Further work to better define this
tentative mechanism is being carried out. SELENBP1 has also
been implicated in ubiquitination from a study demonstrating
the binding of SELENBP1 to von Hippel- Lindau protein
(pVHL)- interacting deubiquitinating enzyme 1 (VDU1) that
was abolished with the incubation of β-mercaptoethanol, which
dissociates selenium (Jeong et al., 2009), suggesting a selenium
dependent interaction of SELENBP1 and VDU1.
Another recent blood based finding has been a reported
increase in lipid biosynthesis in schizophrenia patients treated
with olanzapine vs. untreated patients (Vik-Mo et al., 2008). In
particular the authors found an increase in gene expression of
fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD)
potentially implicating these genes in adverse side effects such as
weight gain. Calcineurin (CaN) has been shown to be down reg-
ulated within the hippocampus of subjects with schizophrenia
(Eastwood et al., 2005) and has also been found to be corre-
lated with psychopathology as measured by the brief psychiatric
rating scale (BPRS) (Murata et al., 2008). Another blood-based
biomarker investigation with a linkage to the brain was car-
ried out by Hattori et al., who demonstrated that in platelets
from patients with schizophrenia gene expression of Fyn, a mem-
ber of the Src-kinase family which targets NMDA receptors
for phosphorylation was increased (Hattori et al., 2009). In a
microarray study looking at gene expression changes in leuko-
cytes of both patients with schizophrenia and bipolar disorder
vs. controls we identified dysregulation of the ubiquitin pro-
teasome system (UPS) using pathway analysis (Bousman et al.,
2010a). Follow-up examination of individual genes within the
UPS showed ubiquitin conjugating enzyme 2 k (UBE2K) and
seven in absentia homolog-2 (SIAH2) had positive correlations
with positive symptom severity (Bousman et al., 2010b). These
findings support previous schizophrenia post-mortem studies
that have reported dsyregulated expression of several ubiquitin-
related genes (Middleton et al., 2002; Altar et al., 2005). A role
for the involvement of GSK3β signaling in schizophrenia has
come from a number of studies including the demonstration that
decreased AKT1 expression was present in the brain and lympho-
cytes of patients with schizophrenia (Emamian et al., 2004) that
was recently replicated for lymphocytes at the gene expression
level (van Beveren et al., 2012). Given GSK3β’s role in neu-
ral development, neurogenesis, neuronal differentiation as well
as synaptic plasticity and axonal growth (Castano et al., 2010;
Hur and Zhou, 2010) and that Akt1 phoshporylates GSK3β to
inactivate these findings within the blood may reflect mecha-
nisms taking place in the brain. These roles are of relevance to
schizophrenia as reductions in synaptic and dendritic markers are
amongst the most consistent post-mortem brain observations for
the disorder (Jarskog et al., 2007). Lastly, there is growing evi-
dence that there may be immune dysregulation in patients with
schizophrenia and recent gene expression investigations within
the blood have demonstrated changes in immune pathways in
patients with schizophrenia (Gardiner et al., 2013; Xu et al., 2012).
Table 1 below summarizes gene expression of biomarkers for
schizophrenia that overlap in the blood and brain.
While blood based gene expression investigation offer great
potential in identifying biomarkers for schizophrenia and psy-
chosis, which could then ultimately be used as diagnostic and
prognostic indicators the discovery of such markers may take
some time to achieve. For blood-based gene expression studies
there are several parameters that can substantially affect gene
expression including diet, genetics, time to last meal, time of
day, any medications used, and frequency of exercise (Radich
et al., 2004). As well as these factors, technology such as microar-
rays while having the utility of assessing global gene expression
changes, present problems in terms of consistency across stud-
ies and laboratorys. Indeed, a number of studies to date, looking
at cross platform comparisons have unfortunately seen a very
low level of correlation in gene expression (Tan et al., 2003;
Hollingshead et al., 2005), even with mRNA samples derived
from homogenous tissue sources such as cell lines. This has led
to the conclusion that gene expression data cannot be combined
reliably between platforms. Knowledge of this result has often
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Table 1 | Gene expression biomarkers for schizophrenia in blood and brain.
Tissue Sample size Gene expression
Gene Platform Category Type N SZ Controls Relative to controls References
CHRNA7 qRT-PCR Blood PBMC 55 34 21 ↓ TNS & SZ Perl et al., 2003
qRT-PCR Blood PBMC 60 44 16 ↓ SZ Perl et al., 2006
qRT-PCR Brain DLPFC 91 30 61 × SZ
qRT-PCR Brain HIP 91 30 61 × SZ Mathew et al., 2007
DARPP-32 qRT-PCR Blood PBMC 15 8 7 ↓ SZ Torres et al., 2009
qRT-PCR Brain DLPFC (BA46) 70 35 35 ↓ SZ-S Feldcamp et al., 2008
qRT-PCR Brain PFC 67 33 34 ↑ SZ Zhan et al., 2011
qRT-PCR Brain DLPFC 502 176 326 ↑ SZ Kunii et al., 2013
DISC1 qRT-PCR Blood PBMC 22 10 11 ↑ TNS & SZ Kumarasinghe et al., 2013
qRT-PCR Brain HIP 91 30 61 ↑ SZ Nakata et al., 2009
DRD2 Custom Blood PBL 23 10 13 ↑ TNS Zvara et al., 2005
qRT-PCR Blood PBMC 56 30 26 × SZ Yao et al., 2008
Affy U133 plus 2.0 Blood PBMC 21 9 12 ↑ SZ Glatt et al., 2011
qRT-PCR Blood PBMC 22 10 11 × TNS & SZ Kumarasinghe et al., 2013
qRT-PCR Brain PFC 67 33 34 × SZ Zhan et al., 2011
DTNBP1 Agilent 18K Blood LCL 24 12 12 ↓ SZ Chagnon et al., 2008
qRT-PCR Blood LCL 90 45 45 × SZ Yamamori et al., 2011
QISH Brain DLPFC 29 14 15 ↓ SZ Weickert et al., 2004
ERRB3 qRT-PCR Blood LCL 59 25 34 ↓ SZ Law et al., 2012
Affy HuGeneFL Brain DLPFC 24 12 12 ↓ SZ Hakak et al., 2001
Affy HgU95A Brain MTG (BA21) 26 12 14 ↓ SZ Aston et al., 2004
Affy U133A&B Brain BA24/32, HIP 26 113 13 ↓ SZ Katsel et al., 2005
qRT-PCR Brain DLPFC 103 31 72 ↓ SZ Law et al., 2012
ERRB4 qRT-PCR Blood LCL 59 25 34 ↑ SZ
qRT-PCR Brain DLPFC 103 31 72 × SZ Law et al., 2012
MAL Affy HuGeneFL Brain DLPFC (BA46) 24 12 12 ↓ SZ Hakak et al., 2001
qRT-PCR Blood PBMC 22 10 11 ↓ TNS; × SZ Kumarasinghe et al., 2013
MBP qRT-PCR Blood PBMC 84 39 45 × TNS & SZ Gutierrez-Fernandez et al., 2010
Affy U133 plus 2.0 Blood PBMC 21 9 12 ↓ SZ Glatt et al., 2011
qRT-PCR Blood PBMC 22 10 11 ↑ TNS; × SZ Kumarasinghe et al., 2013
qRT-PCR Brain PVC (BA17) 30 15 15 ↓ SZ Matthews et al., 2012
MDH1 Custom Blood LCL 14 5 9 ↑ SZ Vawter et al., 2004
Affy HuGeneFL Brain DLPFC (BA46) 24 12 12 ↑ SZ Hakak et al., 2001
UniGEM V2 Brain PFC (BA9) 20 10 10 ↓ SZ Middleton et al., 2002
qRT-PCR Brain DLPFC 43 22 21 ↓ SZ Vawter et al., 2004
NPY1R Custom Blood LCL 14 5 9 ↑ SZ Vawter et al., 2004
qRT-PCR Blood LCL 90 45 45 × SZ Yamamori et al., 2011
Affy HuGeneFL Brain PFC (BA10) 30 15 15 ↓ SZ Kuromitsu et al., 2001
qRT-PCR Brain DLPFC 164 81 82 ↓ SZ Choi et al., 2008
NRG1 Affy U133 plus 2.0 Blood PBL 38 33 5 ↑ SZ Petryshen et al., 2005
Affy U133 plus 2.0 Blood PBL 78 31 47 ↑ FEP Zhang et al., 2008
Agilent 18K Blood LCL 24 12 12 ↓ SZ Chagnon et al., 2008
qRT-PCR Blood LCL 90 45 45 × SZ Yamamori et al., 2011
qRT-PCR Blood PBL 163 80 83 ↓ TNS; × SZ Zhang et al., 2008
(Continued)
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Table 1 | Continued
Tissue Sample size Gene expression
Gene Platform Category Type N SZ Controls Relative to controls References
qRT-PCR Brain DLPFC 39 20 19 ↑ SZa Hashimoto et al., 2004
qRT-PCR Brain HIP 91 38 53 ↑ SZa Law et al., 2006
qRT-PCR Brain PFC (BA10) 19 11 8 ↓ SZa
qRT-PCR Brain PFC (BA10) 19 11 8 ↑ SZb
qRT-PCR Brain PFC (BA9) 19 11 8 × SZ
qRT-PCR Brain HIP 19 11 8 × SZ Parlapani et al., 2010
qRT-PCR Brain PFC (BA9) 12 6 6 ↑ SZ
qRT-PCR Brain HIP 11 6 5 × SZ Marballi et al., 2012
PICK1 Affy U133 plus 2.0 Blood PBMC 21 9 12 ↑ SZ Glatt et al., 2011
qRT-PCR Brain DLPFC 70 35 35 ↑ SZ Sarras et al., 2010
PIK3CD qRT-PCR Blood LCL 59 25 34 ↑ SZ
qRT-PCR Brain DLPFC 103 31 72 × SZ Law et al., 2012
PIK3R3 qRT-PCR Blood LCL 59 25 34 ↑ SZ
qRT-PCR Brain DLPFC 103 31 72 ↑ SZ Law et al., 2012
SELENBP1 qRT-PCR Blood PBMC 58 34 24 ↑ SZ Glatt et al., 2005
qRT-PCR Blood PBMC 56 30 26 × SZ Yao et al., 2008
Affy U133A Brain DLPFC 46 19 27 ↑ SZ Yao et al., 2008
qRT-PCR Brain DLPFC 68 34 34 ↑ SZ Kanazawa et al., 2008
BA, Brodmann area; DLPFC, dorsolateral prefrontal cortex; FEP, first episode psychosis; HIP, hippocampus; LCL, lymphblastoid cell line; MTG, middle temporal
gyrus; PAC, parietal cortex; PBL, peripheral blood lymphocyte; PBMC, peripheral blood mononuclear cell; PFC, prefrontal cortex; PVC, primary visual cortex; QISH,
quantitative in situ hybridization; SZ, schizophrenia; SZ-S, schizophrenia suicide; TNS, treatment niave schizophrenia.
aNRG1 Type I only.
bNRG1 Type II only.
led researchers to choose platforms on the basis of what past
investigations have utilized. While the logic behind this choice is
concrete, it does to a certain extent preclude an informed deci-
sion based on merits of individual platforms. In addition, many
gene expression findings that are discovered through microarray
investigations are often not validated by independent and more
sensitive techniques such quantitative real-time PCR (qRT-PCR).
Nevertheless, with the advent of more sensitive and comprehen-
sive ways to analyse gene expression through next generation
sequencing, the potential of blood based biomarker investigations
may be realized sooner than expected.
MicroRNAs AND DYSREGULATION IN SCHIZOPHRENIA
Current evidence suggests that psychiatric illnesses are not the
result of a dysfunctional single monoamine system but the dis-
ruption of an entire cellular network, schizophrenia being a
prime example of this (Hunsberger et al., 2009). The wide-
ranging effects of miRNA, with their ability to target hundreds
of genes (Hunsberger et al., 2009) make it a molecule of great
interest in schizophrenia research. miRNA are single stranded,
non-coding RNA molecules typically 21-23nt in length (Dinan,
2010). miRNA are able to regulate gene expression by attaching
to mRNA strands based on complementarity of sequence. The
degree to which there is complementarity will influence whether
the mRNA strand targeted is silenced or degraded. Evaluating
miRNAs as biomarkers for schizophrenia is a logical next step as
they have been shown to be key components of gene regulation
in the development of the central nervous system (CNS) (Smrt
et al., 2010; Meza-Sosa et al., 2012). Greater than 50% of identi-
fied miRNAs are expressed either solely or principally in the brain
(Dinan, 2010). Thus, miRNAs could represent a link between the
numerous genes implicated in schizophrenia as they are able to
target hundreds of genes making it capable of explaining the var-
ied aspects of the disease process (Hunsberger et al., 2009). The
dysregulation of miRNA biogenesis leading to abnormal levels of
miRNA in those with schizophrenia or schizoaffective disorders is
an area providing very promising results. A key protein implicated
in this dysregulation is Dgcr8, which is located on chromo-
some 22, (Shiohama et al., 2003) within a section (22q11.2)
known to be deleted in some patients with schizophrenia (Bassett
and Chow, 2008). Santarelli et al. (2011) was able to corroborate
the up-regulation of Dgcr8 while also demonstrating the higher
abundance of Dicer, another molecule involved in miRNA bio-
genesis in schizophrenia patients as compared to normal controls
through utilization of qRT-PCR (Santarelli et al., 2011).
POSTMORTEM miRNA DYSREGULATION IN SCHIZOPHRENIA
Work by (Beveridge et al., 2010) investigating miRNA expres-
sion profiles in both the superior temporal gyrus (STG) and
dorsolateral dlPFC illustrated an important global increase in
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miRNA expression in schizophrenia compared to healthy con-
trols. A total of 59 miRNA were demonstrated to be up-regulated
with the miR-105 family of miRNA as well as miR-107 most
noticeably expressed at higher levels. This miRNA increase is
despite normal pri-miRNA transcripts and gene expression, the
difference lies in the increased pre-miRNA concentration. Key
genes in the biogenesis of miRNA are also up-regulated lead-
ing to the described results. Dgcr8 up-regulation can be found
in the STG while up-regulation of Dgcr8 as well as Drosha and
Dicer1 were demonstrated in the dlPFC (Xu et al., 2008). It
has also been demonstrated that miR-195, which is known to
suppress colorectal carcinoma tumor development in the periph-
ery (Liu et al., 2010), as well as miR-30a-5p down-regulates
the expression of brain derived neurotrophic factor (BDNF)
which consequently cascades into a decreased concentration of
GABAergic genes, principally NPY and somatostatin (SST), in the
dlPFC of schizophrenic patients as compared to unaffected con-
trols (Mellios et al., 2009; Mellios and Sur, 2012). Investigation
revealed that miR-346, a miRNA that targets genes associated
with schizophrenia, is encoded within the glutamate receptor
ionotropic delta 1 (GRID1) gene (Zhu et al., 2009) which itself
was shown previously to be a factor in schizophrenia suscepti-
bility (Treutlein et al., 2009). An investigation of Scandinavian
populations (Danish, Swedish, and Norwegian) looking at 18
single nucleotide polymorphisms (SNPs) revealed two SNPs
(rs17578796 and rs1700) related to miRNAs miR-206 and miR-
198, respectively. These miRNAs showed a significant correlation
to schizophrenia as compared to the control group in Danish and
Norwegian populations. Of the genes targeted by both these miR-
NAs, eight of the 15 are known to be transcription factors or
interaction partners in the network associated with schizophrenia
(Hansen et al., 2007). A further 16 miRNAs that have been found
to be differentially expressed in the PFC between schizophrenia
and normal controls were identified by Perkins et al. (2007), 15
were seen to be expressed at lower levels in those affected and
one was up-regulated. Of the 16 miRNAs, 12 were further inves-
tigated using qRT-PCR with seven of the original miRNAs being
shown to express at significantly lower concentrations. An addi-
tional seven miRNAs have been identified as being dysregulated
in the PFC of schizophrenia patients after an initial investiga-
tion of 667 candidate miRNAs were analysed using a real-time
PCR based Taqman Low Density Array (TLDA). Further study of
miR-34a, miR-132, and miR-212, from the 7 initially identified,
revealed a significant negative correlation between miR-132 and
miR-212 with tyrosine hydroxylase (TH) and phosphogluconate
dehydrogenase (PGD) (Kim et al., 2010). A genome wide associ-
ation study (GWAS) investigating 21,856 subjects with European
ancestry and a further 29,839 independent subjects revealed seven
mi-RNA related SNPs, five of which were new findings (REF).
The strongest correlation was with a SNP, rs1625579, found
in the transcript of miR-137. miR-137 is found on chromo-
some 1p22 in a non-protein-coding RNA gene AK094607 that is
known for its importance to neuronal development (Smrt et al.,
2010). Of the other SNPs found, an additional four of them
were shown to target the same gene (Schizophrenia Psychiatric
Genome-Wide Association Study, 2011). Finally, another recent
post-mortem investigation miRNAs in prefrontal cortices of
patients with schizophrenia and bipolar disorder revealed that
two miRNAs, miR-497 and miR-29c were significantly increased
in patients with bipolar disorder vs. controls (Banigan et al.,
2013). Changes in expression of these two miRNAs may reflect
differences between schizophrenia and bipolar disorder, however,
given that this investigation failed to replicate previous miRNA
findings for the dlPFC brings into question the consistency in
miRNA dysregulation signatures across cohorts. As the miRNA
field progresses attention to treatment related changes in these
markers will prove dividend, with a recent study demonstrating
that some implicated miRNAs for neuropsychiatric disease like,
miR-34a above are regulated significantly by the mood stabilizers
lithium and sodium valproate (Hunsberger et al., 2013).
BLOOD BASED DYSREGULATION OF miRNAs IN SCHIZOPHRENIA
Recently, a blood-based miRNA study using PBMCs reported
the significant down-regulation of 83 miRNA among individu-
als with schizophrenia compared to controls. Of those 83 miRNA
showing down-regulation, 20% were transcribed from a single
maternally expressed, imprinted locus, DLK1-DIO3 (Beveridge
and Cairns, 2012). Another study employed mononuclear leuko-
cytes as the cells of interest and completed a genome wide miRNA
expression profile of 365 miRNA. An miRNA signature compris-
ing seven miRNA for schizophrenia arose, six up-regulated and
one down-regulated. Although these initial results are promis-
ing further work is required to determine the if these observed
effects are a results of antipsychotic, alcohol, and/or illicit drug
exposure rather than underling pathophysiology of schizophre-
nia (Lai et al., 2011). In relation to biomarker investigations
in other living tissues, a recent study has demonstrated that
miR-382 was elevated in the olfactory epithelium taken from
patients with schizophrenia (Mor et al., 2013), this is of sig-
nificance as miR-382 regulates expression of fibroblast growth
factor receptor-1 (FGFR1) that has been previously linked to
schizophrenia (Jungerius et al., 2008).
CONCLUSION
Despite some overlap between structural, cellular, and molecu-
lar data generated from post-mortem investigations, functional
neuroimaging studies and blood-based biomarker investigations,
the full contribution and impact of past post-mortem litera-
ture on biomarker discovery remains to be unearthed. This is
largely due to advantages and disadvantages in these different
modalities to assess alterations in candidate gene and proteins.
For post-mortem investigations, they have the distinct advan-
tage of being able to assess the macro- and microstructure of
the brain in a very detailed way in order to map pathways that
might be affected in schizophrenia. To date this same resolution
cannot be achieved for neuroimaging studies, although the field
is technologically evolving rapidly. Given the growing evidence
for glutamatergic dysregulation as being a potential driver of
schizophrenia and psychosis related pathways, an increase in the
number of functional neuroimaging studies to investigate gluta-
matergic receptor populations is likely. A significant disadvantage
of post-mortem investigations is that they are confounded by
a number of artifacts, including fixation times, post-mortem
interval, and alterations in pH, not to mention trying to account
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for medication effects. Controlling for these variables in post-
mortem studies is challenging, however, with well-characterized
brain cohorts this can be achieved. Nevertheless, differences in
these variables that can influence both gene and protein expres-
sion may account for some discrepancies between post-mortem
and functional neuroimaging studies. With regards to blood
based biomarker research utilizing high throughput technolo-
gies such as microarrays for genotyping and gene expression
are relatively new fields, and therefore time is required for
the full impact of such investigations to providing biomarkers
for diagnosis, prognosis and intervention. While many future
biomarker investigations for schizophrenia and psychosis may
still largely be hypothesis-free, the growing literature and rela-
tive consistency in the data implicating genes such as NRG1 and
the glutamatergic system as a whole are providing researchers
within neuropsychiatric genetics with more mechanistic cor-
relates of these biomarkers. In this way, post-mortem litera-
ture can act to drive blood-based biomarker investigations by
looking for correlates of gene and protein dysfunction within
the blood and also via functional changes using neuroimag-
ing. Although blood-based biomarker investigations are exciting
and have a realistic potential in uncovering candidate genes
and/or proteins relating to schizophrenia, care must be taken
in the interpretation of initial preliminary findings to prevent
generation of spurious paths of research. By implementing care-
ful study design many of these potential confounders can be
reduced or accounted for. In this regard, problems exist in stan-
dardization of diagnosis, collection and processing of samples,
platform design, and evolution in consistency, laboratory tech-
niques, and tools used for analysis (Chow et al., 2012) Other
important potential confounding variables relating to sampling
of mixed proportions of PBMCs, and differences in gene expres-
sion that exist between these (Palmer et al., 2006) as well as
treatment related effects need to be addressed. Investigation
of gene expression changes within separate PBMC subpopula-
tions and treatment related gene expression via in vitro exposure
to various antipsychotic medications may provide one way to
address these concerns. Nonetheless as the field of biomarker
discovery evolves, links with previous post-mortem data and
also current investigations will be made and will potentially
add a level of strength to the validity of such candidates. This
will be aided technologically by more sophisticated and accu-
rate ways of measuring gene expression such as RNAseq and
more sensitive and stringent validation approached such as digital
PCR. A point to bear in mind, and that was already men-
tioned within the introduction is that biomarkers need not nec-
essarily reflect directly brain related changes in patients with
psychosis but instead may be purely associative and related to
symptoms without a clear pathogenic mechanism of involve-
ment. The strength of these biomarkers lies within the predic-
tive capability in deducing susceptibility, diagnosis or potentially
as prognostic indicators, and while a link with brain related
changes may exist and be preferential it may not be evidenced
straight away. Establishing this link between a biomarker and
neuropathophysiology will be one of the ways that future post-
mortem investigations will contribute to resolving biomarkers
for schizophrenia and psychosis. This approach will be bolstered
by investigations of factors such as miRNAs in both blood and
brain compartments and the corroboration of these regulatory
elements.
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